ReviewWorld journal of emergency medicine2012
Novel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis: A systemic review.
Review in World journal of emergency medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Association between high-mobility group box 1 levels and febrile seizures in children: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Dendritic Polyglycerol Sulfate Reduces Inflammation Through Inhibition of the HMGB1/RAGE Axis in RAW 264.7 Macrophages.International journal of molecular sciences · 2025Article
- HMGB1/RAGE Signaling Regulates Th17/IL-17 and Its Role in Bronchial Epithelial-Mesenchymal Transformation.Current molecular medicine · 2024Article
- Plasmin and plasminogen prevent sepsis severity by reducing neutrophil extracellular traps and systemic inflammation.JCI insight · 2023Article
- Electroacupuncture Alleviates Neuroinflammation by Inhibiting the HMGB1 Signaling Pathway in Rats with Sepsis-Associated Encephalopathy.Brain sciences · 2022Article
- High Mobility Group Proteins in Sepsis.Frontiers in immunology · 2022Review
- Molecular mechanisms of lidocaine.Annals of medicine and surgery (2012) · 2021Review
- High-mobility group box1 as an amplifier of immune response and target for treatment inInternational journal of ophthalmology · 2020Article
- The Effects of Remifentanil on Expression of High Mobility Group Box 1 in Septic Rats.Journal of Korean medical science · 2017Article
- Association between HMGB1 and asthma: a literature review.Clinical and molecular allergy : CMA · 2017Review
- Innate immunity gene expression changes in critically ill patients with sepsis and disease-related malnutrition.Central-European journal of immunology · 2015Article
- Clinical analysis of central venous catheter-related infections in patients in the emergency ICU.World journal of emergency medicine · 2013Article
- Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome.World journal of emergency medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh mobility group box 1 protein (HMGB1) is a highly conserved, ubiquitous protein in the nuclei and cytoplasm of nearly all cell types. HMGB1 is secreted into the extracellular milieu and acts as a proinfl ammatory cytokine. In this article we reviewed briefl y the cellular immune response mediated by HMGB1 in infl ammation and sepsis.
methodsThis systemic review is mainly based on our own work and other related reports.
resultsHMGB1 can actively affect the immune functions of many types of cells including T lymphocytes, regulatory T cells (Tregs), dendritic cells (DCs), macrophages, and natural killer cells (NK cells). Various cellular responses can be mediated by HMGB1 which binds to cell-surface receptors [e.g., the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)2, and TLR4]. Anti-HMGB1 treatment, such as anti-HMGB1 polyclonal or monoclonal antibodies, inhibitors (e.g., ethyl pyruvate) and antagonists (e.g., A box), can protect against sepsis lethality and give a wider window for the treatment opportunity.
conclusionHMGB1 is an attractive target for the development of new therapeutic strategies in the treatment of patients with septic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.